
    
      Open-label trial in patients with locally advanced GISTs admitted to Department of Surgery,
      Beijing Cancer Hospital and Institute between April 2010 and May 2013 was carried out
      prospectively. Patients were planned to be treated with imatinib for duration of 6 months
      followed by surgical resection. Postoperative imatinib was planned to be administrated for
      1.5 years. The primary end point was recurrent free survival (RFS) at 2 years; the secondary
      end points included objective response rate (ORR), surgical outcomes and drug safety.
    
  